Clinical Nurse Specialist in Mechanicsville, VA Accepting Medicare

6 Clinical Nurse Specialist nurses found. Showing 1 - 6

Lauren W Turner, CCNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 8266 Atlee Rd, Mechanicsville, VA 23116 Phone: 804-764-7885

Kenley Conley, MSN, RN, ACCNS-AG Clinical Nurse Specialist - Acute Care Medicare: Not Enrolled in Medicare Practice Location: 8260 Atlee Rd, Mechanicsville, VA 23116 Phone: 804-764-7686

Mrs. Michele Ann Smithson, AG-CNS-BC Clinical Nurse Specialist - Adult Health Medicare: Medicare Enrolled Practice Location: 8260 Atlee Rd, Mechanicsville, VA 23116 Phone: 804-764-6000

Rosanna Hastings, NP Clinical Nurse Specialist - Acute Care Medicare: Accepting Medicare Assignments Practice Location: 8243 Meadowbridge Rd, Mechanicsville, VA 23116 Phone: 804-730-1481    Fax: 804-730-8464

Trina Carter, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 8260 Atlee Rd, Mechanicsville, VA 23116 Phone: 804-764-6000

Michelle Milburn, RN, MSN, AGNCS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 8266 Atlee Rd Ste 215, Mechanicsville, VA 23116 Phone: 804-764-7885

News Archive

Financial pressures lead patients, doctors to choose fertility treatments that raise risk of premature birth

While it is well known that fertility treatments are the leading cause of increases in multiple gestations and that multiples are at elevated risk of premature birth, these results are not inevitable, concludes an article in Fertility and Sterility.

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

VOA News examines malaria in southern Sudan

VOA News examines malaria in southern Sudan. In the region, malaria is "widespread" and accounts for "up to 30 percent of all diseases treated by health facilities." It is the "number one killer of children in southern Sudan," though there are "no reliable statistics on the number in southern Sudan who suffer, or die from, malaria," VOA News reports.

Read more Medical News

› Verified 5 days ago